Sparta Biomedical — Early Feasibility Study of Bionic Cartilage in Colombia and the Dominican Republic
Sparta Biomedical's Ormi™ implant and Galene® bionic cartilage—a synthetic matrix replicating natural cartilage for osteoarthritis—were studied in an early feasibility study in Colombia and the Dominican Republic run with bioaccess®.
Study facts
- Sponsor / company: Sparta Biomedical
- Indication / area: Orthopedics
- Country: Colombia, Dominican Republic
- Study type: Early Feasibility Study (EFS)
Key metrics
- Budget: Scope-based (illustrative, not a quote)
- Follow-up: 12 months
The challenge
Osteoarthritis has no regenerative treatment option. Sparta Biomedical needed early human feasibility data for its bionic cartilage implant.
bioaccess® solution
bioaccess® designed and executed an early feasibility study in Colombia and the Dominican Republic, managing site selection with top orthopedic surgeons, patient recruitment of knee osteoarthritis patients, implant logistics, and structured follow-up assessments.
Results
- Early feasibility study conducted in Colombia and the Dominican Republic
Frequently asked
- What did bioaccess® do for Sparta Biomedical?
- bioaccess® designed and executed an early feasibility study in Colombia and the Dominican Republic, managing site selection with top orthopedic surgeons, patient recruitment of knee osteoarthritis patients, implant logistics, and structured follow-up assessments.
- Where was the Sparta Biomedical Early Feasibility Study (EFS) study run?
- The Sparta Biomedical Early Feasibility Study (EFS) study was executed in Colombia, Dominican Republic by bioaccess® in the orthopedics area.
- What was the outcome of the Sparta Biomedical study?
- Reported outcomes for Sparta Biomedical's device: Early feasibility study conducted in Colombia and the Dominican Republic.
Run a similar trial: Clinical trials in Colombia · Clinical trials in Dominican Republic
First-in-Human Clinical Trials pillar · LATAM FIH Benchmarks 2026 · ← All case studies · Contact bioaccess®